Leverage Shares 2X Long CBRS Daily ETF (CBRG)
$2.98
Pre-market−0.06 (−2.13%)
At close$3.05(+13.62%)
Phytanix Bio Publishes New Investor Deck Highlighting Strategic Vision and Growth Potential
NEW YORK and SANTA BARBARA, Calif., July 30, 2024 – Phytanix Bio, a pioneering preclinical stage pharmaceutical company dedicated to the development of therapeutics based on cannabinoid and cannabinoid-like molecules, today announced the release of its new investor deck.
Phytanix Bio Publishes New Investor Deck Highlighting Strategic Vision and Growth Potential
NEW YORK and SANTA BARBARA, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Phytanix Bio, a pioneering preclinical stage pharmaceutical company dedicated to the development of therapeutics based on cannabinoid and cannabinoid-like molecules, today announced the release of its new investor deck.